{"DataElement":{"publicId":"6712217","version":"1","preferredName":"Population Pharmacokinetic Study Coagulation Factor VIII Standard Half Life Chromogenic Substrate Clotting Factor Assay","preferredDefinition":"A study of the process by which a drug is absorbed, distributed, metabolized, and eliminated by the body._Coagulation factor VIII (2351 aa, ~267 kDa) is encoded by the human F8 gene. This protein plays a role in the modulation of coagulation factor IX activity and blood coagulation._A document, established by consensus and approved by a recognized body, that provides, for common and repeated use, rules, guidelines or characteristics for activities or their results._The amount of time needed for a material to lose half of its physical, chemical, or biological activity._Any finite or infinite collection of subjects from which a sample is drawn for a study to obtain estimates for values that would be obtained if the entire population were sampled. [AMA style Manual]_A reagent containing purified coagulation factors (FIXa, FX and thrombin) in optimal concentrations is added to test plasma in the first stage, which does not rely on the extrinsic or intrinsic initiation pathways as the thrombin activates FVIII. The amount of FXa generated in the first stage is measured by its action on a specific chromogenic substrate, which releases a chromophore upon cleavage. The color intensity produced is directly proportional to the amount of FXa, which in turn is directly proportional to the FVIII activity in the sample.","longName":"Popu_Phar_FVIII_Stan_Half_Assa","context":"PhenX","contextVersion":"1","DataElementConcept":{"publicId":"6712205","version":"1","preferredName":"Population Pharmacokinetic Study Coagulation Factor VIII Standard Half Life","preferredDefinition":"A study of the process by which a drug is absorbed, distributed, metabolized, and eliminated by the body._Coagulation factor VIII (2351 aa, ~267 kDa) is encoded by the human F8 gene. This protein plays a role in the modulation of coagulation factor IX activity and blood coagulation._A document, established by consensus and approved by a recognized body, that provides, for common and repeated use, rules, guidelines or characteristics for activities or their results._The amount of time needed for a material to lose half of its physical, chemical, or biological activity._Any finite or infinite collection of subjects from which a sample is drawn for a study to obtain estimates for values that would be obtained if the entire population were sampled. [AMA style Manual]","longName":"Popu_Phar_FVIII_Stan_Half","context":"PhenX","contextVersion":"1","ObjectClass":{"publicId":"6706636","version":"1","preferredName":"Population Group Pharmacokinetic Study","preferredDefinition":"A group of individuals united by a common factor (e.g., geographic location, ethnicity, disease, age, gender):A study of the process by which a drug is absorbed, distributed, metabolized, and eliminated by the body.","longName":"C17005:C49663","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Population Group","conceptCode":"C17005","definition":"A group of individuals united by a common factor (e.g., geographic location, ethnicity, disease, age, gender)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Pharmacokinetic Study","conceptCode":"C49663","definition":"A study of the process by which a drug is absorbed, distributed, metabolized, and eliminated by the body.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"871581F0-C744-1C0F-E053-F662850AAFE3","latestVersionIndicator":"Yes","beginDate":"2019-04-21","endDate":null,"createdBy":"PANH","dateCreated":"2019-04-21","modifiedBy":"ONEDATA","dateModified":"2019-04-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"6706645","version":"1","preferredName":"Coagulation Factor VIII Standard Half Life","preferredDefinition":"Coagulation factor VIII (2351 aa, ~267 kDa) is encoded by the human F8 gene. This protein plays a role in the modulation of coagulation factor IX activity and blood coagulation.:A document, established by consensus and approved by a recognized body, that provides, for common and repeated use, rules, guidelines or characteristics for activities or their results.:The amount of time needed for a material to lose half of its physical, chemical, or biological activity.","longName":"C16571:C81893:C70916","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Coagulation Factor VIII","conceptCode":"C16571","definition":"Coagulation factor VIII (2351 aa, ~267 kDa) is encoded by the human F8 gene. This protein plays a role in the modulation of coagulation factor IX activity and blood coagulation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Standard","conceptCode":"C81893","definition":"A document, established by consensus and approved by a recognized body, that provides, for common and repeated use, rules, guidelines or characteristics for activities or their results.","evsSource":"CTCAE_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Half Life","conceptCode":"C70916","definition":"The amount of time needed for a material to lose half of its physical, chemical, or biological activity.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8715E320-D7EF-1BF9-E053-F662850A970E","latestVersionIndicator":"Yes","beginDate":"2019-04-21","endDate":null,"createdBy":"PANH","dateCreated":"2019-04-21","modifiedBy":"ONEDATA","dateModified":"2019-04-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008557","version":"1","preferredName":"Lab Results","preferredDefinition":"the results of laboratory tests.","longName":"LAB_RESULTS","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B2CFBA7D-D009-7227-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-27","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-27","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"87362511-B21C-24FC-E053-F662850A59E3","latestVersionIndicator":"Yes","beginDate":"2019-04-23","endDate":null,"createdBy":"PANH","dateCreated":"2019-04-23","modifiedBy":"PANH","dateModified":"2019-08-02","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"6732893","version":"1","preferredName":"Chromogenic Substrate Clotting Factor Assay","preferredDefinition":"A reagent containing purified coagulation factors (FIXa, FX and thrombin) in optimal concentrations is added to test plasma in the first stage, which does not rely on the extrinsic or intrinsic initiation pathways as the thrombin activates FVIII. The amount of FXa generated in the first stage is measured by its action on a specific chromogenic substrate, which releases a chromophore upon cleavage. The color intensity produced is directly proportional to the amount of FXa, which in turn is directly proportional to the FVIII activity in the sample.","longName":"6732893v1.0","context":"PhenX","contextVersion":"1","type":"Non-enumerated","dataType":"NUMBER","minLength":null,"maxLength":null,"minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[],"ConceptualDomain":{"publicId":"2008557","version":"1","preferredName":"Lab Results","preferredDefinition":"the results of laboratory tests.","longName":"LAB_RESULTS","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B2CFBA7D-D009-7227-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-27","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-27","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"6732892","version":"1","preferredName":"Chromogenic Substrate Clotting Factor Assay","preferredDefinition":"A reagent containing purified coagulation factors (FIXa, FX and thrombin) in optimal concentrations is added to test plasma in the first stage, which does not rely on the extrinsic or intrinsic initiation pathways as the thrombin activates FVIII. The amount of FXa generated in the first stage is measured by its action on a specific chromogenic substrate, which releases a chromophore upon cleavage. The color intensity produced is directly proportional to the amount of FXa, which in turn is directly proportional to the FVIII activity in the sample.","longName":"C159552","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Chromogenic Substrate Clotting Factor Assay","conceptCode":"C159552","definition":"A reagent containing purified coagulation factors (FIXa, FX and thrombin) in optimal concentrations is added to test plasma in the first stage, which does not rely on the extrinsic or intrinsic initiation pathways as the thrombin activates FVIII. The amount of FXa generated in the first stage is measured by its action on a specific chromogenic substrate, which releases a chromophore upon cleavage. The color intensity produced is directly proportional to the amount of FXa, which in turn is directly proportional to the FVIII activity in the sample.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"8770746D-BEB4-5DD5-E053-F662850A3A40","latestVersionIndicator":"Yes","beginDate":"2019-04-26","endDate":null,"createdBy":"PANH","dateCreated":"2019-04-26","modifiedBy":"ONEDATA","dateModified":"2019-04-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8770746D-BEC5-5DD5-E053-F662850A3A40","latestVersionIndicator":"Yes","beginDate":"2019-04-26","endDate":null,"createdBy":"PANH","dateCreated":"2019-04-26","modifiedBy":"PANH","dateModified":"2019-08-02","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"2793652","version":"1","longName":"PhenX","context":"PhenX","ClassificationSchemeItems":[{"publicId":"6641385","version":"1","longName":"Hemophilia","context":"PhenX"}]}],"AlternateNames":[],"ReferenceDocuments":[{"name":"Data Element Population Pharmacokinetic Study Coagulation Factor VIII Standard Half Life Chromogenic Substrate Clotting Factor Assay does not have Preferred Question Text","type":"Preferred Question Text","description":"Data Element Population Pharmacokinetic Study Coagulation Factor VIII Standard Half Life Chromogenic Substrate Clotting Factor Assay does not have Preferred Question Text","url":null,"context":"PhenX"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Standard","id":"873875FA-5572-6F2C-E053-F662850AC079","latestVersionIndicator":"Yes","beginDate":"2019-04-23","endDate":null,"createdBy":"PANH","dateCreated":"2019-04-23","modifiedBy":"PANH","dateModified":"2020-06-15","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}